Active substance | Avacopan |
Holder | Vifor Fresenius Medical Care Renal Pharma Ltd. |
Status | Running |
Indication | in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) |
Public documents | Approbation |
Information for the patient | |
Informed consent | |
Last update | 05/09/2022 |